Tag: <span>moderna</span>

Home / moderna
Post

Clarification on WHO statement about COVID-19 vaccine interchangeability

The media has recently reported that a physician associated with the World Health Organization (WHO) suggested that the mixing of vaccines was a ‘dangerous trend’. This was not an official statement by the World Health Organization. The statement was made at a session unrelated to vaccine mixing and was taken out of context by news...

Post

Real World Evidence for COVID-19 Vaccines

Similar to clinical trials, real world cohort and case-control studies find COVID-19 infections are reduced by >90% with two doses of mRNA vaccines. Single doses of either mRNA or AstraZeneca vaccine decreases infections by ~60% and hospitalizations by 70-80%. Vaccine effectiveness appears similar for variants of concern and are safe for pregnant women. HMC

Post

Updated information on AstraZeneca/COVISHIELD COVID-19 vaccines

On June 29, 2021, Health Canada issued a Health Product Risk Communication regarding the AstraZeneca/COVISHIELD COVID-19 vaccine: https://healthycanadians.gc.ca/recall-alert-rappel- avis/hc-sc/2021/75389a-eng.php Health Canada has updated the product monograph for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary leak syndrome as a potential side effect following vaccination. Patients with a history of capillary leak syndrome should not...

Post

Second dose of COVID-19 Vaccination

NACI has provided updated recommendations on COVID-19 vaccine schedules. For those who have received a first dose of an AstraZeneca vaccine, an mRNA vaccine is preferred for the second dose due to emerging evidence suggesting better immune response, and, to mitigate the risk of VITT(Vaccine-Induced Thrombotic Thrombocytopenia) from viral vector vaccines. HMC

Post

Second Dose COVID-19 Vaccine Type-Interchangeability, Updated on June3, 2021

NACI recommends that persons who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated. On June 1, the Public Health Agency of Canada released updated recommendations from the National Advisory Committee on Immunization (NACI) on the interchangeability of authorized...

Post

Interchangeability of COVID-19 vaccines

As per the Ministry of Health’s guidance on the Administration of the AstraZeneca COVID-19/COVISHIELD vaccine, individuals who have received one dose of the AstraZeneca/COVIDSHIELD vaccine, should receive a second dose of the AstraZeneca/COVISHIELD vaccine to complete their vaccination series.  HMC

Post

COVID-19 Vaccination of the Senior 65+ Population

Peel residents aged 65-69 are now eligible to get vaccinated for COVID-19 at hospital clinics. Appointments for the 65-69 age group will also be expanded to Peel Public Health community clinic sites in the coming days. In alignment with the Ministry’s Guidance for Prioritization of Phase 2 Populations for COVID-19 Vaccination, individuals with the following conditions, along...

Post

More COVID-19 Vaccine Info

 Dear Patients,  As you all know, the first vaccines are being given to higher risk people and health care workers. But we look forward to when we will have access to the vaccine. We do not yet know the place or the timing and we will communicate this when we do.  Some questions have arisen that...

Post

COVID-19 Vaccines

Dear community members and families, In the last few weeks, we have seen significant movement in our understanding of the COVID-19 vaccines. As of today, here is what we know: The vaccines are safe The vaccines approved for use in Canada work by sending a message to our body’s immune system to stimulate our natural immune response....

Post

Important Safety Information on the Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels – Moderna Biopharma Canada Corporation

Moderna COVID-19 Vaccine was authorized for use in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. As an extraordinary measure to provide earlier access to vaccine supplies in the context of the global pandemic, Moderna is providing, at this time, vaccine vials and cartons...

Post

3 Approved COVID-19 Vaccines Efficacy

Interim results of two large randomized, placebo-controlled trials (RCTs) demonstrate ~95% relative efficacy in preventing COVID-19 (Pfizer, Moderna). The AstraZeneca/Oxford vaccine has ~70% relative efficacy. Absolute benefits will vary with baseline risk and time but if annual risk of developing COVID-19 is 20%, then vaccine would decrease risk to 1% (6% with AstraZeneca/Oxford). These vaccines...